Rhythm Pharmaceuticals Inc (RYTM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.97B
Last updated: Nov 17, 2026 at 11:06 AM ET
Rhythm Pharmaceuticals Inc (RYTM) Stock Forecast
Analysts expect Rhythm Pharmaceuticals (RYTM) to earn -$4.94 per share in the fiscal year ending Dec 31, 2026, on revenue of $330.56M. Of 19 analysts, 17 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 19 ratings average 1.84, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 89% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 26.3% |
| Buy | 12 | 63.2% |
| Hold | 2 | 10.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 19
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 74.9%.
- Fiscal year ending Dec 31, 2026
- -$4.94
- EPS consensus, revenue $330.56M
- Fiscal year ending Dec 31, 2027
- -$1.30
- EPS consensus, revenue $578.18M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.94 | -$7.93 to -$1.25 | 14 | $330.56M | $317.10M to $341.00M | 17 |
| Dec 31, 2027 | -$1.30 | -$4.55 to -$0.04 | 12 | $578.18M | $415.60M to $655.70M | 18 |
Quarterly Estimates
The EPS consensus rises from -$1.59 for the quarter ending Dec 31, 2026 to -$0.69 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.59 | -$5.46 to -$0.07 | 21 | $109.32M | $97.12M to $123.90M | 19 |
| Mar 31, 2027 | -$0.69 | -$0.91 to -$0.45 | 4 | $112.15M | $93.65M to $120.00M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 10 upward and 8 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 0 |
| Fiscal year ending Dec 31, 2027 | 3 | 7 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.07.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.94 | -$3.04 | -$3.10 | -$3.07 | -$3.07 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.30 | -$0.63 | -$0.61 | -$0.61 | -$0.61 | N/A |
| Quarter ending Mar 31, 2027 | -$0.69 | -$0.71 | -$0.75 | -$0.75 | -$0.75 | N/A |
Frequently Asked Questions About RYTM
What is the RYTM stock forecast?
Consensus analyst estimates put Rhythm Pharmaceuticals's EPS at -$4.94 for the fiscal year ending Dec 31, 2026, on revenue of $330.56M. The consensus rating from 19 analysts is Buy.
How do analysts rate RYTM stock?
Of 19 analysts covering Rhythm Pharmaceuticals, 5 rate it Strong Buy, 12 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RYTM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.94, with estimates from -$7.93 to -$1.25 from 14 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.30, with estimates from -$4.55 to -$0.04 from 12 analysts.
What revenue do analysts expect from Rhythm Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $330.56M, with estimates from $317.10M to $341.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $578.18M, with estimates from $415.60M to $655.70M.
How many analysts cover RYTM?
19 analysts rate Rhythm Pharmaceuticals stock, and 14 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RYTM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors